Tri Locum Partners LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1826434) · Explore on the interactive board
Tri Locum Partners LP disclosed 19 US equity positions worth $813.2m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is JNJ at 13.3% of the reported book, followed by VRTX, LLY. The top ten holdings are 80.0% of the book, and the portfolio behaves like about 13 equal-weight positions. Versus the prior filing it opened 5 new positions, added to 8, reduced 6 and exited 3. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Tri Locum Partners LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 5 new, 8 added, 6 reduced, 3 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | JNJ JOHNSON & JOHNSON | Healthcare | 13.3% | $107.9m | 424,945 | 3% | added |
| 2 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 12.3% | $100.2m | 201,791 | 56% | added |
| 3 | LLY ELI LILLY & CO | Healthcare | 11.3% | $91.8m | 76,532 | 24% | added |
| 4 | ASND ASCENDIS PHARMA A/S | Healthcare | 8.5% | $69.0m | 258,740 | – | new |
| 5 | DXCM DEXCOM INC | Healthcare | 6.8% | $55.3m | 820,479 | 18% | added |
| 6 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 6.6% | $53.7m | 219,308 | 253% | added |
| 7 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 6.6% | $53.4m | 221,720 | 40% | added |
| 8 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 5.4% | $44.0m | 866,716 | – | new |
| 9 | ARGX ARGENX SE | Healthcare | 4.7% | $38.6m | 41,596 | 31% | added |
| 10 | MDGL MADRIGAL PHARMACEUTICALS INC | Healthcare | 4.5% | $36.7m | 68,273 | -34% | reduced |
| 11 | RVMD REVOLUTION MEDICINES INC | Healthcare | 3.5% | $28.4m | 151,822 | – | new |
| 12 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 3.1% | $25.5m | 47,026 | -33% | reduced |
| 13 | TEVA TEVA PHARMACEUTICAL INDS LTD | Healthcare | 3.1% | $25.3m | 746,835 | -27% | reduced |
| 14 | TARS TARSUS PHARMACEUTICALS INC | Healthcare | 2.5% | $20.7m | 328,340 | 30% | added |
| 15 | ISRG INTUITIVE SURGICAL INC | Healthcare | 2.3% | $19.1m | 47,983 | -69% | reduced |
| 16 | CYTK CYTOKINETICS INC | Healthcare | 2.0% | $16.5m | 194,000 | – | new |
| 17 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 1.4% | $11.8m | 120,712 | -17% | reduced |
| 18 | BBNX BETA BIONICS INC | Healthcare | 1.0% | $7.7m | 493,344 | – | new |
| 19 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 0.9% | $7.7m | 162,996 | -56% | reduced |
What did Tri Locum Partners LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| TMO THERMO FISHER SCIENTIFIC INC | 42.0% | $65.1m |
| ASND ASCENDIS PHARMA A/S | 37.7% | $58.4m |
| NUVALENT INC | 20.4% | $31.6m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 100.0% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Tri Locum Partners LP's portfolio?
Across every quarter Tri Locum Partners LP has filed, its median largest position is 13.7% of the book and its median top-ten weight is 80.8%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 2.0 completed holding spells, the median lasted 1.0 quarters; 19.0 positions are still open and their final length is unknown.